Title |
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA‐B) genotype and allopurinol dosing: 2015 update
|
---|---|
Published in |
Clinical Pharmacology & Therapeutics, July 2015
|
DOI | 10.1002/cpt.161 |
Pubmed ID | |
Authors |
Y Saito, L K Stamp, K E Caudle, M S Hershfield, E M McDonagh, J T Callaghan, W Tassaneeyakul, T Mushiroda, N Kamatani, B R Goldspiel, E J Phillips, T E Klein, M T M Lee |
Abstract |
The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B*58:01 Genotype and Allopurinol Dosing was originally published in February 2013. We reviewed recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the supplemental material and included additional resources for applying CPIC guidelines into the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org). This article is protected by copyright. All rights reserved. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 100% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Science communicators (journalists, bloggers, editors) | 1 | 100% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 1 | 1% |
Unknown | 78 | 99% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 13 | 16% |
Student > Ph. D. Student | 9 | 11% |
Student > Bachelor | 9 | 11% |
Student > Master | 7 | 9% |
Professor > Associate Professor | 6 | 8% |
Other | 16 | 20% |
Unknown | 19 | 24% |
Readers by discipline | Count | As % |
---|---|---|
Pharmacology, Toxicology and Pharmaceutical Science | 16 | 20% |
Biochemistry, Genetics and Molecular Biology | 15 | 19% |
Medicine and Dentistry | 10 | 13% |
Nursing and Health Professions | 3 | 4% |
Agricultural and Biological Sciences | 3 | 4% |
Other | 9 | 11% |
Unknown | 23 | 29% |